A healthy diet is a cornerstone to preventing cardiovascular disease, but many healthcare providers receive insufficient nutrition education and training, according to a new scientific advisory released by the American Heart Association.

A late-breaking study presented at SCAI 2018 demonstrated that patients who stay in the hospital for more than 72 hours after transcatheter aortic valve replacement (TAVR) are more likely to die in the following year than those with earlier discharges.

Operators trained in the hybrid approach to PCI of chronic total occlusions (CTOs) demonstrated technical and procedural success rates of 87 percent and 85 percent, respectively, in a multicenter international trial.

A post-approval study of Abbott’s MitraClip device showed positive one-year results for the first 2,000 patients entered into the national Transcatheter Valve Therapy registry, according to late-breaking science presented April 26 at SCAI 2018 in San Diego.

Two studies suggest patients with cardiac-related hospitalizations—specifically for aortic dissection and ST-segment elevation myocardial infarction (STEMI)—are admitted more frequently and have higher mortality rates during winter months.

A new meta-analysis found double antithrombotic therapy following PCI for patients with atrial fibrillation (AFib) was associated with 47 percent fewer bleeding events than triple therapy and similar rates of major adverse cardiac events.

The family of a newlywed nurse is suing American Airlines after she fell ill on a flight and died. The cause of her death was determined to be an acute massive pulmonary embolism and cardiogenic shock.

A small study presented at SCAI 2018 demonstrated the potential of 3D printing to help clinicians select the appropriate size for transcatheter heart valves and avoid paravalvular leak (PVL).

TITUSVILLE, N.J., April 27, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results of a real-world study showing that adults with type 2 diabetes initiated on INVOKANA® (canagliflozin) 300mg had significantly better blood glucose control, based on A1C goal attainment and reduction, compared to similar patients initiated on Farxiga®(dapagliflozin) 10mg.

A combination of prediabetes and hypertension increases the risk for cardiovascular disease (CVD) more than either risk factor alone, according to new research published April 18 in Hypertension.